Vaccination

Glenmark announces 400 mg 'FabiFlu' for Covid-19 treatment

Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral - FabiFlu -- for the treatment of mild to moderate Covid-19 in India. Aug 7, 2020
corona vaccine

India's Hetero wins approval to sell COVID drug favipiravir

India's Hetero Labs Ltd has received regulatory approval to sell its version of anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Wednesday, as coronavirus infections in the world's third worst-hit nation crossed 1.5 million. Jul 29, 2020